PDK4 Antibody - BSA Free

Western Blot: PDK4 Antibody - BSA Free [NBP1-07047] -

Western Blot: PDK4 Antibody - BSA Free [NBP1-07047] - Genetic manipulations can alter PDH E1 alpha phosphorylation in response to hypoxia.(a) MIA PaCa-2 control (Hg), silenced HIF1 alpha (shHIF1 alpha) or silenced PDHK1 (shPDHK1) & PDP1 overexpressing cells were incubated for 16 h in normoxia or hypoxia (0.5% O2) & phospho-serine E1 alpha detected by Western blot showing that all three modifications can have an inhibitory effect on hypoxic Ser232 phosphorylation. (b) Increased pSer232-E1 alpha detection after E1 alpha immunoprecipitation from lysates of cells treated as in (a). (c) The same analysis as in (a) after treatment with 16 h 1 mM DMOG. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/27498883), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PDK4 Antibody - BSA Free [NBP1-07047] -

Western Blot: PDK4 Antibody - BSA Free [NBP1-07047] - Hypoxia inhibits mitochondrial OCR & PDH activity & induces PDHK1 protein & activity.(a) Ratio of oxygen consumption rate (OCR) to extracellular acidification rate (ECAR) measured by Seahorse XF in MIA PaCa-2, PANC-1, & SU.86.86 cell lines in high (25 mM) or low (0.5 mM) glucose incubated overnight with or without 1 mM DMOG. (mean ± SEM, two-tailed Student’s t-test, **p < 0.01, ***p < 0.001) (b) Cell-based PDH activity assay in cells incubated 16 h in normoxia, hypoxia (0.5% O2) or 1 mM DMOG. (mean ± SD, one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001) (c) Western blots of HIF alpha isoforms, pyruvate dehydrogenase kinase isoforms (PDHKs), phosphatase (PDP1 – lower band *), target phosphorylated serine residues on E1 alpha & total E1 alpha after overnight incubation in normoxia or hypoxia (0.5% O2) at 25 or 5 mM glucose as indicated. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/27498883), licensed under a CC-BY license. Not internally tested by Novus Biologicals.